HNPMI

CAS No. 1980848-48-3

HNPMI( —— )

Catalog No. M37340 CAS No. 1980848-48-3

HNPMI is an EGFR inhibitor that induces G0/G1 phase arrest of CRC cells in colorectal cancer, regulates enzymes associated with apoptosis, and can promote apoptosis, and can be used for the study of colorectal cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 53 Get Quote
10MG 88 Get Quote
25MG 174 Get Quote
50MG 273 Get Quote
100MG 439 Get Quote
500MG 954 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    HNPMI
  • Note
    Research use only, not for human use.
  • Brief Description
    HNPMI is an EGFR inhibitor that induces G0/G1 phase arrest of CRC cells in colorectal cancer, regulates enzymes associated with apoptosis, and can promote apoptosis, and can be used for the study of colorectal cancer.
  • Description
    HNPMI is an inhibitor of EGFR and has cytotoxic effects on tumor cells. HNPMI can downregulate the protein levels of osteopontin, survivin and cathepsin S, leading to apoptosis. HNPMI also regulates BCL-2/BAX and p53 in CRC cell lines to inhibit tumorigenesis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    Apoptosis | EGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1980848-48-3
  • Formula Weight
    360.41
  • Molecular Formula
    C22H20N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=[N+]([O-])C1=CC=C(C(C(N2C3=C(CC2)C=CC=C3)C4=CC=C(C)C=C4)=C1)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kandhavelu J, et al. A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL-2/BAX and p53 in colon cancer. Br J Pharmacol. 2024 Jan;181(1):107-124.?
molnova catalog
related products
  • TJ191

    TJ191 is a selective anti-cancer agent, targeting low TβRIII-expressing malignant T-cell leukemia/lymphoma cells.

  • Imexon

    A 2-cyanoaziridine derivative with antitumor activity in some types of cancer.

  • Valinomycin

    Valinomycin is a cyclic depsipeptide antibiotic and a potassium-specific ionophore.Valinomycin induces PINK1 activation and promotes Parkin phosphorylation at Ser65.